Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02034110
Title Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors GlaxoSmithKline
Indications

thyroid gland cancer

gastrointestinal stromal tumor

biliary tract cancer

germ cell cancer

multiple myeloma

high grade glioma

hairy cell leukemia

small intestine adenocarcinoma

Therapies

Dabrafenib + Trametinib

Age Groups: adult
Covered Countries USA | CAN

Facility Status City State Zip Country Details
Novartis Investigative Site Little Rock Arkansas 72205 United States Details
Novartis Investigative Site Santa Monica California 90404 United States Details
Novartis Investigative Site Bethesda Maryland 20892 United States Details
Novartis Investigative Site Boston Massachusetts 02114 United States Details
Novartis Investigative Site Boston Massachusetts 02215 United States Details
Novartis Investigative Site New York New York 10016 United States Details
Novartis Investigative Site Nashville Tennessee 37203 United States Details
Novartis Investigative Site Houston Texas 77030 United States Details
Novartis Investigative Site Innsbruck 6020 Austria Details
Novartis Investigative Site Linz 4010 Austria Details
Novartis Investigative Site Salzburg A-5020 Austria Details
Novartis Investigative Site Wien 1090 Austria Details
Novartis Investigative Site Jette 1090 Belgium Details
Novartis Investigative Site Toronto Ontario M5G 2M9 Canada Details
Novartis Investigative Site Koebenhavn Oe 2100 Denmark Details
Novartis Investigative Site Bordeaux Cedex 33076 France Details
Novartis Investigative Site Caen Cedex 9 14 033 France Details
Novartis Investigative Site Dijon Cedex 21079 France Details
Novartis Investigative Site Lille Cedex 59020 France Details
Novartis Investigative Site Lyon cedex 03 69437 France Details
Novartis Investigative Site Nantes cedex 1 44093 France Details
Novartis Investigative Site Saint-Herblain 44805 France Details
Novartis Investigative Site Strasbourg Cedex 67091 France Details
Novartis Investigative Site Toulouse Cedex 9 31059 France Details
Novartis Investigative Site Villejuif Cedex 94805 France Details
Novartis Investigative Site Freiburg Baden-Wuerttemberg 79106 Germany Details
Novartis Investigative Site Heidelberg Baden-Wuerttemberg 69120 Germany Details
Novartis Investigative Site Mannheim Baden-Wuerttemberg 68167 Germany Details
Novartis Investigative Site Tuebingen Baden-Wuerttemberg 72076 Germany Details
Novartis Investigative Site Berlin 13353 Germany Details
Novartis Investigative Site Hamburg 20246 Germany Details
Novartis Investigative Site Roma Lazio 00128 Italy Details
Novartis Investigative Site Milano Lombardia 20132 Italy Details
Novartis Investigative Site Milano Lombardia 20133 Italy Details
Novartis Investigative Site Milano Lombardia 20141 Italy Details
Novartis Investigative Site Verona Veneto 37134 Italy Details
Novartis Investigative Site Chiba 277-8577 Japan Details
Novartis Investigative Site Tokyo 104-0045 Japan Details
Novartis Investigative Site Seoul 06273 Korea, Republic of Details
Novartis Investigative Site Seoul 110-744 Korea, Republic of Details
Novartis Investigative Site Seoul 135-710 Korea, Republic of Details
Novartis Investigative Site Seoul 138-736 Korea, Republic of Details
Novartis Investigative Site Amsterdam 1066 CX Netherlands Details
Novartis Investigative Site Amsterdam 1081 HV Netherlands Details
Novartis Investigative Site Nijmegen 6525 GA Netherlands Details
Novartis Investigative Site Rotterdam 3075 EA Netherlands Details
Novartis Investigative Site Utrecht 3584 CX Netherlands Details
Novartis Investigative Site Oslo 0310 Norway Details
Novartis Investigative Site Barcelona 08035 Spain Details
Novartis Investigative Site Madrid 28041 Spain Details
Novartis Investigative Site Pamplona 31008 Spain Details
Novartis Investigative Site Stockholm SE-171 76 Sweden Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field